24
total announcements
544529.BO · 15 min delayed
Aptus Pharma Ltd
Aptus Pharma Ltd has allotted 15,97,470 equity shares on a preferential basis to 188 allottees at Rs. 280 per share, aggregating Rs. 44,72,91,600. The issued, subscribed, and paid-up equity share capital of the company has increased from Rs. 17,15,00,000 to Rs. 18,74,74,700.
Aptus Pharma Ltd
Aptus Pharma Ltd has informed BSE that a Board of Directors meeting is scheduled on 12/11/2026 to consider and approve the allotment of equity shares on a preferential basis to proposed allottees, subject to receipt of subscription money and compliance with applicable statutory and regulatory requirements.
Aptus Pharma Ltd
Aptus Pharma Ltd has received in-principle approval from BSE Ltd for a proposed preferential issue of equity shares, as approved by shareholders at their Annual General Meeting on September 14, 2026.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced the transcript of its Q2 FY27 Earnings Call, providing insights into its financial performance for the half-year ended September 30, 2026, and its long-term strategic vision.
Aptus Pharma Ltd
Aptus Pharma Ltd has uploaded the audio recording of its earnings call for the half year ended September 30, 2026, on its website. The company has complied with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced an investor presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the half year ended 30th September, 2026, highlighting its financial results, business overview, and future growth prospects.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced an earnings call for the quarter and half year ended September 30, 2026, to be held on October 26, 2026, at 5:00 PM IST. The management will discuss the financial performance, recent business developments, future business plans, growth strategies, and business outlook.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced its unaudited financial results for the half year ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors. The company's unaudited financial results have been approved by the Board of Directors. The trading window for trading in the shares of the company will open from October 23, 2026.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced its unaudited financial results for the half year ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors. The company's Board of Directors has approved the financial results, and the trading window for trading in the shares of the company will open from October 23, 2026.
Aptus Pharma Ltd
Aptus Pharma Ltd has scheduled a Board Meeting on 20/10/2026 to consider and approve Unaudited Financial Results for the Half Year ended on September 30, 2026 and to close the Trading Window.
Aptus Pharma Ltd
Aptus Pharma Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter and half year ended on 30th September, 2026.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced the closure of its trading window under the Insider Trading Code, effective from October 1, 2026, until the completion of 48 hours after the declaration of its half-yearly financial results for September 30, 2026.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced the results of its 16th Annual General Meeting (AGM) held on September 14, 2026, along with the Scrutinizer's Report. The meeting saw a total of 13,938,000 votes cast, with all three resolutions passed unanimously.
Aptus Pharma Ltd
Aptus Pharma Ltd held its 16th Annual General Meeting (AGM) on September 14, 2026, through video conferencing. The meeting was attended by 28 members, and the requisite quorum was present throughout. The company's statutory auditors, secretarial auditor, and scrutinizer were also present. The meeting was conducted in compliance with applicable provisions of the Companies Act, 2013, and SEBI Listing Regulations.
Aptus Pharma Ltd
Aptus Pharma Ltd has submitted a newspaper advertisement for the Corrigendum to the Notice of the 16th Annual General Meeting, which was published in The Indian Express and Financial Express.
Aptus Pharma Ltd
Aptus Pharma Ltd announces its next growth phase with focus on manufacturing, pan-India expansion, and global markets. The company plans to raise ₹44.88 crore through a preferential issue of equity shares and utilize the funds for capital expenditure, working-capital requirements, and general corporate purposes.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced an investor presentation under Regulation 30 of SEBI (LODR) Regulations, 2015, for the year ended 31st March, 2026, which includes financial results and a company overview.
Aptus Pharma Ltd
Aptus Pharma Ltd has submitted its Annual Report for FY 2025-26, including the Notice of Annual General Meeting, Directors Report, Independent Auditors Report, and Audited Financial Statements.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced its 16th Annual General Meeting (AGM) to be held on September 14, 2026, through video conferencing. The meeting will consider the adoption of financial statements, appointment of a director, and approval of a preferential allotment of equity shares.
Aptus Pharma Ltd
Aptus Pharma Ltd has announced the outcome of its board meeting, where it considered and approved the final number of allottees and the number of equity shares to be issued on a preferential basis. The company also determined and approved the issue price for the proposed preferential issue of 16,02,870 equity shares, based on the valuation report obtained from the Registered Valuer.